What Happens When FDA Category 2 Peptides Move to FDA Category 1?
What leaders should know if the regulatory landscape shifts
Updated: May 6, 2026
The one question that many leaders have is this: if Category 2 peptides move to Category 1, what might actually happen next?
Peptide compounding regulations have evolved considerably under the 503A interim compounding policy, causing uncertainty among healthcare executives and compounding stakeholders.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) has scheduled a two-day public meeting for July 23–24, 2026, where the Committee will review whether seven peptides should be added to the Section 503A Bulk Drug Substances List. It's the most concrete regulatory milestone on this topic in years.
We'll explore what might occur given the shifting PCAC reviews, reclassification discussions, and more — so you can be prepared.
What do Category 1 and Category 2 mean under FDA’s interim 503A policy?
Before we jump into what would happen, let’s first clarify how Category 1,Category 2, and Category 3 peptide APIs differ based on the FDA’s 503A interim compounding policy.
It’s important to note: this category framework applies to substances that were already categorized prior to the FDA’s January 7, 2025, guidance. New substances are no longer being placed into these categories.
Category | What It Means | Can It Be Compounded? |
Category 1 | Sufficient safety information; eligible for compounding while under FDA review | Yes, with a valid patient-specific prescription |
Category 2 | Does not meet interim 503A compounding policy requirements. | No, prohibited in human compounding due to significant safety risks |
Category 3 | Insufficient data to evaluate | No, lacking enough documentation or evidence for the FDA to properly evaluate them |
The July 2026 PCAC Meeting: What's on the Table
On July 23, 2026, the Committee will discuss BPC-157-related bulk drug substances, KPV-related bulk drug substances, TB-500-related bulk drug substances, and others being considered for inclusion on the 503A Bulks List. On July 24, the Committee will turn to Emideltide (also referred to as delta sleeping inducing peptide, or DSIP), Semax-related bulk drug substances, and Epitalon-related bulk drug substances.
These peptides have been discussed in the context of conditions including ulcerative colitis, wound healing, obesity, insomnia, opioid withdrawal, inflammatory conditions, and osteoporosis, among others.
An additional five peptides will be considered at a PCAC meeting to be held before the end of February 2027.
What's important to understand is what a PCAC review actually is — and isn't. The Committee's role is advisory. Its recommendations inform the FDA's path forward, but they don't constitute final rulemaking. The FDA requires formal rulemaking before compounding pharmacies may act on a reclassification, even with a favorable PCAC outcome. The July meeting marks the beginning of that process, not the end of it.
For background on which peptides have been at the center of this conversation, see our blog on which peptides could become legal again.
The analysis typically considers four factors: the physical and chemical characterization of the substance, any safety issues raised by its use in compounding, the available evidence of effectiveness for the use, and historical use of the substance.
What Would FDA Likely Need to See Before a Category 2 Could Move to a Category 1?
In practical terms, a move from Category 2 to Category 1 would mean the substance could come within FDA’s interim enforcement policy for 503A compounders. That is narrower than a final regulatory blessing, but it is still meaningful. It can affect how quickly some pharmacies, prescribers, and health-service brands assess operational readiness.
According to the January 2025 guidance, the FDA evaluates each substance using four key criteria:
The physical and chemical characterization of the substance
Any safety issues raised by its use in compounded drug products
Historical use in compounded drug products, including conditions treated
Available evidence of effectiveness, or lack thereof
These factors are considered together, and no single criterion determines the outcome. The July PCAC meeting is where that evaluation begins in earnest for seven substances.
Does a Category 2-to-Category 1 move end FDA review?
No. FDA’s January 2025 guidance makes clear that the category framework is still only an interim policy while the agency develops the 503A bulks list. FDA evaluates substances with input from expert advisors and the U.S. Pharmacopeia, uses notice-and-comment rulemaking, and then publishes final rules identifying which substances will and will not appear on the 503A bulks list.
That means a Category 1 placement is best understood as an interim enforcement position, not the final word.
So What Would Change if a Category 2 Peptide API Moved to Category 1?
With this context in mind, if Category 2 peptides were moved to Category 1, they’d fall within the FDA’s 503A interim enforcement policy.
In practical terms, that means the FDA would generally not intend to take action against 503A pharmacies compounding them for individual patients with a valid prescription, assuming all other applicable conditions are met.
But let’s break down exactly what that process might look like in practice.
Would Compounding Be Allowed Immediately and Without Constraints?
No. Even if a peptide moved into Category 1, a 503A pharmacy would still need to satisfy the conditions FDA and the statute lay out. They are as follows:
1. Sourcing Requirements Would Still Apply
Reclassification doesn’t change the sourcing rules. Under section 503A and the FDA’s January 2025 guidance, bulk drug substances must be manufactured by an FDA-registered establishment and accompanied by a valid certificate of analysis. They must also satisfy the applicable statutory sourcing requirements.
2. Compounding Remains Tied to Patient-Specific Prescribing
Category 1 status doesn’t create a wholesale or manufacturing pathway. Drug products compounded under section 503A are intended for identified individual patients with valid prescriptions. That said, the FDA does allow limited anticipatory compounding in advance of receiving those prescriptions.
3. The FDA Review Process Continues in the Background
A favorable PCAC recommendation in July would not be a final regulatory determination. The FDA would still complete its evaluation and proceed through notice-and-comment rulemaking before making a final inclusion decision on the 503A bulks list. Depending on where the substance sits in that pipeline, the process could take years.
What should brands, telehealth platforms, and pharmacy partners do now?
The July 23–24 PCAC meeting creates a concrete opportunity for operational preparation, but the safest move is readiness, not promotional urgency.
Start with the basics:
Confirm your pharmacy partner's 503A process and documentation standards
Verify source traceability, FDA registration status, and certificate-of-analysis procedures for bulk ingredients
Review prescribing workflows to ensure they are built around valid patient-specific prescriptions, with only limited anticipatory compounding where the law allows it
Align patient education, consent, and marketing language so you are not implying FDA approval or guaranteed availability
Review state telehealth, pharmacy, and advertising requirements before launch or expansion
The PCAC calendar gives you a window to prepare. The organizations that move thoughtfully now will be in the strongest position to act if and when reclassification moves forward. For a practical look at what that readiness entails operationally, see our guide on how to launch new care programs faster.
Be Ready for Any Peptide Reclassification with OpenLoop Health
Peptide compounding regulations are still evolving, and the FDA's scheduled PCAC review of seven peptides this July could shift access quickly. For organizations that prefer not to build this infrastructure internally, OpenLoop provides support across key operational and regulatory components:
Access to compounded medications through licensed 503A pharmacy partners (where permitted by law)
Medically reviewed, repeatable protocols
Licensed clinician network with credentialing and oversight across all 50 states
Compliance-aligned infrastructure designed to adapt as federal and state regulations evolve
Patient support services available 24/7/365
You focus on your brand. OpenLoop bring the infrastructure support. Contact our team to get started.
This content is for general informational purposes only and does not constitute legal or medical advice. Regulatory classifications are subject to change. Consult qualified legal counsel and clinical advisors for guidance specific to your organization.
*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.